Backed by an Austin venture group, Navegate has opened a Houston outpost. Courtesy of Navegate

A growing software company backed by Austin-based Next Coast Ventures has set its eyes on a new office in Houston.

Navegate, a digital supply chain technology and services for the middle market with headquarters in Minneapolis and offices in Chicago, Los Angeles, and Shanghai, announced its new offices in Houston and Kansas City as well as a the beta version of a new software platform. The company now has 100 employees across its six offices.

"At Navegate we have a concierge-level commitment to fulfilling our clients' needs," says Nathan Dey, CEO of Navegate, in a news release. "By establishing Kansas City and Houston offices, we're expanding our footprint to have physical locations in two critical freight hubs. These locations will provide further leverage for both existing and future Navegate clients in their efforts to build best-in-class supply chains."

James Blodgett will lead the Houston office as the key accounts manager. He has more than 35 years of experience in project cargo, according to the release, and notes how important Houston is as a market considering its connection to the port.

"As a hub for cargo and oversized shipments, I'm excited to leverage our new location to strengthen customer relationships as well as grow Navegate's base for project cargo," says Blodgett in the release.

The company has financial support in Texas already. Next Coast Ventures originally got involved with the company last October when Chicago-based Saltspring Capital led Navegate's financing round. Dey, who was previously managing partner at Saltspring Capital, became CEO and chairman of Navegate as part of the recapitalization.

"Nathan has only been CEO at Navegate for less than a year and he has already done an incredible job of reinvigorating the company's mission to be the industry leader in logistics, strategically growing their global presence and incorporating customer feedback into their platform," says Michael Smerklo, co-founder and managing director of Next Coast Ventures. "Navegate's newly-designed software and commitment to having their experts on the ground in these transportation hubs show their unwavering dedication to their customers — the exact type of hands-on, innovative approach to customer service and product iteration that we strive to invest in."

The company announced that Operations Manager Adam Daugherty will lead the new Kansas City location, and that it will be rolling out a new platform, called Navegate Emerald™. The new user interface is complete with intelligent new shipment tracking and management tools that work with supply chain collaboration. Navegate Emerald has four new applications that allows customization for customers to build their own solutions depending on their needs.

"As we celebrate our 50th year in business, Navegate Emerald has ushered in a renaissance of our technology and our business as a whole," says Dey in the release. "We're thrilled to be able to help add value to our more than 600 clients' processes and transform how they do business through the utilization of these digitally-enabled supply chain tools. The breakthrough business benefits they provide will allow for reduced supply chain costs, better working capital management, improved understanding of capital at risk and more seamless communication with all supply chain constituents.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”